Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Athira Pharma, Inc. - Common Stock
(NQ:
ATHA
)
0.5131
-0.0629 (-10.92%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
275,978
Open
0.5500
Bid (Size)
0.5102 (1)
Ask (Size)
0.5599 (3)
Prev. Close
0.5760
Today's Range
0.5125 - 0.5700
52wk Range
0.4115 - 4.298
Shares Outstanding
38,054,583
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND
December 06, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
November 07, 2024
Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025
From
Athira Pharma, Inc.
Via
GlobeNewswire
Performance
YTD
-82.25%
-82.25%
1 Month
-18.23%
-18.23%
3 Month
+22.17%
+22.17%
6 Month
-78.35%
-78.35%
1 Year
-77.09%
-77.09%
More News
Read More
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 05, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
November 01, 2024
Via
Benzinga
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
November 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
November 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
October 31, 2024
Via
Benzinga
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
October 22, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Robinhood To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Thursday
September 19, 2024
Via
Benzinga
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
September 17, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings
September 04, 2024
Via
Benzinga
Exposures
Fossil Fuels
US Stocks Mixed; Trade Gap Widens In July
September 04, 2024
Via
Benzinga
Athira Pharma's Alzheimer's Candidate Fails To Improve Cognition And Function In Patients With Mild/Moderate Disease, Stock Sinks
September 04, 2024
Via
Benzinga
Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
September 04, 2024
Via
Benzinga
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease
September 03, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
ATHA Stock Earnings: Athira Pharma Beats EPS for Q2 2024
August 01, 2024
Via
InvestorPlace
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates
August 01, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024
July 31, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
July 09, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
June 12, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
June 11, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Participate in Upcoming June Conferences
May 29, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
May 17, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024
May 15, 2024
Via
InvestorPlace
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
May 15, 2024
From
Athira Pharma, Inc.
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.